English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, June 18, 2020
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial
Monday, April 27, 2020
华领医药宣布Dorzagliatin与恩格列净(一种SGLT-2抑制剂)联合用药临床研究的成功结果
華領醫藥宣佈Dorzagliatin與恩格列淨(一種SGLT-2抑制劑)聯合用藥臨床研究的成功結果
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Monday, March 16, 2020
华领医药公布2019年全年业绩
華領醫藥公佈2019年全年業績
Hua Medicine Announces 2019 Annual Results
Friday, February 14, 2020
华领医药任命前美国FDA官员汤福兴博士为首席技术官
華領醫藥任命前美國FDA官員湯福興博士為首席技術官
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575